Trial · NCT04731103
Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome
NCT04731103, Phase 2, Completed, University of Edinburgh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome. Trials, record NCT04731103. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04731103
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome
- NCT number
- NCT04731103
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- University of Edinburgh
- Conditions
- Aicardi-Goutières Syndrome
- Interventions
- Abacavir (ABC), Lamivudine (3TC), Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)
- First posted
- 2021-01-29
- Last updated
- 2024-05-09
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determine if the use of the reverse transcriptase inhibitors abacavir (ABC), lamivudine (3TC) and zidovudine (AZT) reduces Interferon (IFN) signalling in patients with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C or SAMHD1 | At 6 weeks | The primary outcome is a change in the Interferon(IFN) score over baseline at 6 weeks end of treatment. |
| Secondary | A change in interferon alpha protein levels | 6 weeks | Change in interferon alpha protein levels (fg/ml) over 6 weeks per treatment arm. |
| Secondary | A change in cerebral blood flow | 6 weeks | Change in cerebral blood flow (ml/min/100g of tissue) over 6 weeks per treatment arm. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30566312 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04731103
GET https://conductscience.org/api/trials/v1/NCT04731103/registered